Evidence map›Paper›PMID 38382529›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.

Fei Liu, Sarah T Ryan, Kelly C Fahnoe, Jennifer G Morgan, Anne E Cheung, Michael J Storek, Alejandro Best, Hui A Chen, Monica Locatelli, Shuyun Xu and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 3 countries.

Fei LiuQ32 Bio, Waltham, MA 02451, USA.
Sarah T RyanQ32 Bio, Waltham, MA 02451, USA.
Kelly C FahnoeQ32 Bio, Waltham, MA 02451, USA.
Jennifer G MorganQ32 Bio, Waltham, MA 02451, USA.
Anne E CheungQ32 Bio, Waltham, MA 02451, USA.
Michael J StorekQ32 Bio, Waltham, MA 02451, USA.
Alejandro BestArkana Laboratories, Little Rock, AR 77211, USA.
Hui A ChenDepartment of Pathology and Laboratory Medicine, Chobanian and Avedisian School of Medicine at Boston University and Boston Medical Center, Boston, MA 02118, USA.
Monica LocatelliIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, 24126 Bergamo, Italy.
Shuyun XuDepartment of Pathology, Brigham & Women's Hospital/Harvard Medical School, Boston, MA 02115, USA.
Enno SchmidtLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Leon F Schmidt-JiménezLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Katja BieberLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Joel M HendersonDepartment of Pathology and Laboratory Medicine, Chobanian and Avedisian School of Medicine at Boston University and Boston Medical Center, Boston, MA 02118, USA.
Christine G LianDepartment of Pathology, Brigham & Women's Hospital/Harvard Medical School, Boston, MA 02115, USA.
Admar VerschoorDepartment of Otorhinolaryngology, Technische Universität München and Klinikum Rechts der Isar, 81675 Munich, Germany; Department of Dermatology, University Hospital Schleswig-Holstein, University of Lübeck, 23562 Lübeck, Germany.
Ralf J LudwigLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Ariela BenigniIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, 24126 Bergamo, Italy.
Giuseppe RemuzziIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, 24126 Bergamo, Italy.
David J SalantDepartment of Medicine, Chobanian and Avedisian School of Medicine at Boston University and Section of Nephrology, Boston Medical Center, Boston, MA 02118, USA.
Susan L KalledQ32 Bio, Waltham, MA 02451, USA.
Joshua M ThurmanDepartment of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA.
V Michael HolersDepartment of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA.
Shelia M VioletteQ32 Bio, Waltham, MA 02451, USA.
Stefan WawersikQ32 Bio, Waltham, MA 02451, USA. Electronic address: swawersik@q32bio.com.
N2 Biomedical (United States) · USUniversity of Lübeck · DEMario Negri Institute for Pharmacological Research · ITBoston Medical Center · USUniversity of Colorado Anschutz Medical Campus · USArkana Laboratories · USBoston University · USBrigham and Women's Hospital · USHarvard University · USTechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic treatments raise infection risk in patients. To address these challenges, we developed antibody fusion proteins combining the alternative-pathway complement inhibitor factor H (fH

Indexed as

Complement Factor HKidney DiseasesAnimalsAntibodiesComplement ActivationComplement C3dHumansMiceRatsAntibodiesComplement C3dComplement Factor HC3dcomplementfactor Hglomerular diseaseskin diseasetissue-targeted

Identifiers

PMID38382529
PMCPMC11163200
OpenAlexW4391973051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.